Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Botulinum neurotoxin serotype A (BoNT/A) is a potent neurotoxic protein produced by *Clostridium botulinum*. It functions as a zinc-dependent endopeptidase that cleaves SNAP25, a SNARE protein essential for acetylcholine release at neuromuscular junctions. This leads to flaccid paralysis and is the basis for its therapeutic and cosmetic uses in conditions like dystonia, spasticity, migraine, hyperhidrosis, and wrinkle reduction. BoNT/A exerts its effects through a multi-step process involving binding to neuronal receptors (gangliosides and SV2), internalization, translocation of the light chain into the cytosol, and catalytic cleavage of SNAP25. In nature, it exists in complex with non-toxic proteins that enhance its oral toxicity.
Cleaves SNAP25, a SNARE protein essential for synaptic vesicle fusion, thereby blocking acetylcholine release at neuromuscular junctions. This results in prolonged but reversible muscle paralysis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Botulinum Neurotoxin Serotype A (BoNT/A).